

1. Record Nr.	UNINA9910807355903321
Autore	Randleman J. Bradley
Titolo	Refractive surgery : an interactive case-based approach / / J. Bradley Randleman
Pubbl/distr/stampa	Thorofare, New Jersey : , : SLACK Incorporated, , 2014 ©2014
ISBN	9781630910228 1-63091-022-8
Descrizione fisica	1 online resource (240 p.) : color illustrations
Disciplina	617.755
Soggetti	Eye - Accommodation and refraction Refractive keratoplasty
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references.
Sommario/riassunto	"Refractive Surgery : An Interactive Case-Based Approach presents all of the necessary refractive surgery material to make an informed decision regarding diagnosis and management plans. Rather than utilizing the standard organization of most books, where major points are first introduced and then explained through a series of writings and references, this book relies on the clinical decision-making process involved with treating refractive surgery patients. Refractive Surgery: An Interactive Case-Based Approach by Dr. J. Bradley Randleman builds upon foundational initial chapters through the case presentations and focused case discussions, encompassing the major topics in refractive surgery today. For each case, the critical question is simply, "what data in this chart is the most critical to consider when evaluating this patient for surgery?" Refractive Surgery: An Interactive Case-Based Approach is unique in its format. Specifically, the book facilitates active learning by forcing the reader to think through a series of questions surrounding each patient scenario. This active learning not only facilitates better recall of the information presented but also mimics the actual physician-to-patient clinical experience, making this book more relevant than other routine refractive surgery books. Bonus! This

dynamic learning tool is also supplemented by interactive online video material to further the learning experience. Enhance the clinical decision-making process by watching the videos and then answering a series of questions that lead to the conclusion of each scenario"--
Provided by publisher.

2. Record Nr.	UNINA9911019658503321
Autore	Sofia Michael J
Titolo	Trends in Antiviral Drug Development
Pubbl/distr/stampa	Newark : , : John Wiley & Sons, Incorporated, , 2025 ©2025
ISBN	3-527-84509-7 3-527-84510-0 3-527-84508-9
Edizione	[1st ed.]
Descrizione fisica	1 online resource (531 pages)
Collana	Trends in Drug Discovery Series
Altri autori (Persone)	WangZhengqiang FischerJános KleinChristian ChildersWayne E RotellaDavid P
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Cover -- Half Title Page -- Title Page -- Copyright -- Contents -- Preface -- Introduction: Successes and Challenges in Antiviral Drug Development -- Introduction -- Antiviral Drugs Targeting Human Herpesviruses -- Antiviral Drugs Targeting Human Immunodeficiency Virus -- Drugs Targeting Reverse Transcriptase -- Drugs Targeting Protease -- Drugs Targeting Integrase Strand Transfer -- Drugs Targeting Viral Entry -- Drugs Targeting Viral Capsid -- Antiviral Drugs Targeting Hepatitis B Virus -- Antiviral Drugs Targeting Hepatitis Delta Virus -- Antiviral Drugs Targeting Hepatitis C Virus -- Antiviral Drugs Targeting Acute RNA Respiratory Viruses -- Drugs Targeting Human

Influenza Viruses -- Drugs Targeting SARS-CoV-2 -- New Trends and Challenges in Antiviral Drug Development -- References -- Part I: Human Herpes Viruses -- Chapter 1: Letermovir for the Prevention of CMV Infection in Transplant Recipients -- 1.1 Background -- 1.1.1 Cytomegalovirus -- 1.1.2 Immunocompromised Patients -- 1.1.3 Patient Groups with a High Risk for CMV Complications -- 1.1.4 Available CMV Treatments Before Letermovir -- 1.1.4.1 Antiviral Drugs -- 1.1.4.2 Dominant Treatment Strategies -- 1.1.4.3 Unmet Medical Need -- 1.2 Discovery Phase -- 1.3 Preclinical Characterization -- 1.3.1 Antiviral Potency/Selectivity/Inhibitory Profile -- 1.3.1.1 In Vitro Potency Versus Laboratory CMV Strains -- 1.3.1.2 In Vitro Potency Versus Clinical CMV Isolates and Resistance-breaking Profile -- 1.3.1.3 In Vivo Efficacy (Xenotransplant Model) -- 1.3.1.4 In Vitro Antiviral Specificity -- 1.3.1.5 Other Characteristics of Letermovir's Inhibitory Profile -- 1.3.1.6 Summary -- 1.4 Mechanism of Action Studies -- 1.4.1 Target Identification -- 1.5 Terminase Inhibitors -- 1.5.1 Previous and Contemporary Drug Candidates Targeting the Terminase Complex. -- 1.5.2 Letermovir: Same Target, Different Interaction -- 1.5.3 Advantages of Terminase Inhibitors -- 1.6 Preclinical Safety Evaluation -- 1.7 Clinical Development and MAA/NDA Submission -- 1.7.1 Regulatory Support for Clinical Development -- 1.7.2 Phase 1 -- 1.7.2.1 Drug-Drug Interaction Studies -- 1.7.2.2 Special Populations -- 1.7.2.3 IV Formulation -- 1.7.3 Clinical Proof-of-concept -- 1.7.3.1 Phase 2a Clinical Trial (AIC001-2-001) -- 1.7.3.2 Emergency IND Treatment of a Lung Transplant Patient with Multiresistant CMV Disease -- 1.7.3.3 Credentials Established -- 1.7.4 Letermovir for CMV Prophylaxis in HSCT Patients -- 1.7.4.1 Phase 2b: First Prophylaxis Trial in HSCT Patients -- 1.7.4.2 Phase 3 CMV Prophylaxis Trial in HSCT Patients -- 1.7.4.3 Marketing Approval in HSCT Recipients -- 1.7.4.4 Further Clinical Development and Real-world Data -- 1.7.4.4.1 Phase 3 Trial for Extension of the Prophylaxis Period -- 1.7.4.4.2 Follow-up Trials in Specific Populations -- 1.7.5 Letermovir for CMV Prophylaxis in KT Patients -- 1.7.5.1 Phase 3 Noninferiority Trial in KT Recipients -- 1.7.5.2 Marketing Approval in KT Recipients -- 1.7.5.3 Further Clinical Development and Real-world Data -- 1.8 Drug Resistance -- 1.8.1 Genetic Characterization of Letermovir Resistance -- 1.9 Letermovir Resistance in Clinical Trials -- 1.10 Real-world Resistance -- 1.11 Outlook for Letermovir -- Acknowledgments -- References -- Chapter 2: Discovery and Development of the Helicase-Primase Inhibitor Pritelivir for the Treatment of Immunocompromised Patients with Resistant HSV Infection -- 2.1 HSV Virology and Disease -- 2.2 Treatment -- 2.3 Resistant Infections -- 2.4 Pritelivir Discovery and Target Identification -- 2.5 Nonclinical Data -- 2.5.1 In Vitro Studies -- 2.5.2 In Vivo Studies -- 2.5.2.1 Guinea Pig Model for Genital HSV-2 Infection -- 2.5.2.2 Mouse Model for HSE. -- 2.5.2.3 Pritelivir in Immunocompromised Mouse Model -- 2.6 Clinical Data -- 2.6.1 Phase 1 Program -- 2.6.2 Genital HSV -- 2.6.3 Resistant Infections -- 2.7 Pritelivir Resistance -- 2.8 Conclusion and Outlook -- References -- Part II: Immunodeficiency Virus -- Chapter 3: The Discovery and Early Development of the HIV-1 Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) -- 3.1 Introduction -- 3.2 Medicinal Chemistry -- 3.2.1 Discovery of S/GSK1349572 (DTG) -- 3.2.1.1 Evolution of the Chemical Structure Leading to DTG -- 3.3 Virology -- 3.3.1 In Vitro Studies Indicated Robust Efficacy and High Barrier to Resistance of DTG -- 3.4 Clinical Development -- 3.4.1 PK Studies Supported Once-daily 50 mg Dosing of DTG -- 3.4.2 Clinical Studies in People Living with HIV-1 -- 3.4.3 Clinical Studies in

Individuals with Prior Treatment Failure -- Acknowledgments --
References -- Chapter 4: The Discovery and Development of Islatravir
(4'-Ethynyl-2-fluoro-2'-deoxyadenosine [EFdA], MK-8591) -- 4.1
Introduction -- 4.2 HIV Replication Cycle -- 4.3 Structure and Function
of HIV RT -- 4.4 DNA Synthesis by RT -- 4.5 RT Inhibitor Classes --
4.6 EFdA Development -- 4.6.1 4'-Ethynyl Ribose Modifications --
4.6.2 2-Fluoro Adenosine Modifications -- 4.6.3 3'-Hydroxy Ribose
Modification -- 4.7 EFdA: A Compound with 4'-Ethynyl, 2-Fluoro, and
3'-Hydroxy Modifications -- 4.7.1 Effects of the 4'-Ethynyl Modification
on EFdA -- 4.7.2 Effects of the 2'-Fluoro Modification on EFdA -- 4.7.3
Effects of the 3'-Hydroxy Modification on EFdA -- 4.7.3.1 Mechanisms
of Inhibition: EFdA -- 4.7.3.1.1 Biochemical Mechanisms of Inhibition
-- 4.7.3.1.2 Structural Mechanisms of Inhibition -- 4.8 Mechanism of
Resistance/Hypersusceptibility to EFdA -- 4.8.1 Mechanisms of Viral
Resistance to EFdA -- 4.8.2 Mechanisms of Viral Hypersusceptibility to
EFdA.
4.8.3 Combination Therapies with EFdA -- 4.8.4 Synthesis Advances --
4.9 Animal Studies -- 4.9.1 EFdA Pharmacokinetic Studies in Rodents
-- 4.9.2 EFdA Antiviral Activity in Humanized Mice -- 4.9.3 EFdA
Antiviral Activity in Rhesus Macaques -- 4.9.4 EFdA Long-acting
Activity in Various Animals -- 4.10 Clinical Trials -- 4.11 Long-acting
Methods of Delivery for EFdA Treatment -- 4.12 NRTTIs as a Drug
Class -- References -- Part III: Hepatitis Viruses -- Chapter 5:
Discovery of the RNA Interference Therapeutic Imdusiran, a GalNAc-
conjugated siRNA -- 5.1 Introduction -- 5.2 Comparison of Preclinical
Anti-HBV Efficacy Between Lipid Nanoparticle-encapsulated and
GalNAc-conjugated siRNA -- 5.3 Comparison of Tetravalent Versus
Trivalent GalNAc Ligands -- 5.4 siRNA Selection: Comparison of siRNA
Activity Against HBsAg and HBx Targets -- 5.5 Imdusiran Design and
Preclinical Characterization -- 5.5.1 Abrogation of siRNA
Immunostimulatory Potential -- 5.5.2 Imdusiran siRNA Target Site
Sequence -- 5.6 Imdusiran Antiviral Activity -- 5.6.1 Imdusiran
Antiviral Activity in Primary Mouse and Human Hepatocyte HBV Models
-- 5.6.2 Imdusiran In Vivo Antiviral Activity -- 5.7 Imdusiran
Combination Treatment -- 5.7.1 Imdusiran Combination with Standard
of Care and Investigational Agents -- 5.8 Perspectives -- References --
Chapter 6: Discovery and Development of ARO-HBV/JNJ-3989 -- 6.1
Introduction -- 6.1.1 Chronic Hepatitis B Virus Infection -- 6.1.1.1 HBV
Structure and Associated Molecular and Cellular Biology -- 6.1.1.1.1
Clinical Course of HBV Infection -- 6.2 Development of RNAi
Therapeutic ARO-HBV/JNJ-73763989 (JNJ-3989) -- 6.2.1 RNAi as a
Therapeutic Modality -- 6.2.2 Use of siRNA to Treat HBV Infection --
6.2.2.1 JNJ-3989 siRNAs Have Broad Cross-reactivity to HBV Genotypes
and HBV Transcripts.
6.2.2.1.1 Reduction of Serum HBsAg, HBeAg, and HBV DNA in Mouse
Model of Chronic HBV Infection -- 6.3 Pharmacokinetics and Safety of
JNJ-3989 in Humans -- 6.4 Clinical Studies in Chronically HBV-infected
Patients -- 6.4.1 Direct Antiviral Treatment Approach with JNJ-3989-
based Regimens -- 6.4.1.1 Pharmacological Response to JNJ-3989 with
Short-term Treatment -- 6.4.1.2 REEF-1 Clinical Study -- 6.4.1.3
REEF-2 Clinical Study -- 6.4.2 Combination Approaches of JNJ-3989
with Immune Modulation -- 6.4.2.1 PENGUIN Clinical Study -- 6.4.2.2
REEF-IT Clinical Study -- 6.4.3 HBsAg Targeting siRNA JNJ-3989 in
Chronic Hepatitis D -- 6.4.3.1 REEF-D Clinical Study -- 6.5 Discussion
and Perspectives -- References -- Chapter 7: The Discovery and
Development of Sofosbuvir as the Backbone of HCV Curative Therapies
-- 7.1 Introduction -- 7.2 Identification of the 2'-F, 2'- β -C-Methyl
Cytidine Nucleoside PSI-6130 -- 7.3 Identification of the 3',5'-

Diisobutyrate Ester Prodrug RG7128 and Clinical Proof-of-concept --
7.4 Development of the 5'-Phosphoramidate Uridine Nucleotide
Prodrug for Liver Targeting and Clinical Proof-of-concept -- 7.5
Sofosbuvir: The Backbone of HCV Curative Therapies -- 7.6 Conclusion
-- References -- Chapter 8: The Discovery and Development of
Harvoni® and Epclusa®: Ending the Interferon Era -- Curing All
Hepatitis C Genotypes -- 8.1 Cure -- 8.2 Introduction -- 8.3 The
Discovery of Ledipasvir [13-15] -- 8.4 Early Development of Ledipasvir
-- 8.5 Ledipasvir/Sofosbuvir STR Clinical Trial Results and Real-world
Effectiveness -- 8.6 Initiation of a Pangenotypic NS5A Inhibitor
Program -- 8.7 Discovery of the Pangenotypic NS5A Inhibitor
Velpatasvir [40-42] -- 8.8 The Development of Velpatasvir -- 8.9
Clinical Trial Efficacy and Real-world Effectiveness with the
Pangenotypic Sofosbuvir/Velpatasvir STR -- 8.10 Conclusion --
Acknowledgment.
Compliance with Ethical Standards.
